APO Research
Talk to an analyst

APO RESEARCH · REPORT

Renin-Angiotensin-System (RAS)-Acting Agent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Renin-Angiotensin-System (RAS)-Acting Agent Market Outlook and Growth Opportunities 2026

22 December 2025194 pages

Choose your research edition.

Industry ResearchRenin-Angiotensin-System (RAS)-Acting Agent Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Renin-Angiotensin-System (RAS)-Acting Agent Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Renin-Angiotensin-System (RAS)-Acting Agent Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Renin-Angiotensin-System (RAS)-Acting Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Renin-Angiotensin-System (RAS)-Acting Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Renin-Angiotensin-System (RAS)-Acting Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Renin-Angiotensin-System (RAS)-Acting Agent market include Takeda Pharmaceutical Company Limited, Sanofi S.A., Johnson & Johnson, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company,Limited, AstraZeneca plc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Renin-Angiotensin-System (RAS)-Acting Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Renin-Angiotensin-System (RAS)-Acting Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Renin-Angiotensin-System (RAS)-Acting Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Renin-Angiotensin-System (RAS)-Acting Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Company

Takeda Pharmaceutical Company Limited

Sanofi S.A.

Johnson & Johnson

Novartis AG

Merck & Co., Inc.

Pfizer, Inc.

Daiichi Sankyo Company,Limited

AstraZeneca plc

Bristol-Myers Squibb Company

Boehringer lngelheim GmbH

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Type

Angiotensin Converting Enzyme Inhibitors (ACEi)

Angiotensin Receptor Blockers (ARBs)

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Application

Heart Failure

Chronic Kidney Disease

Hypertension

Other

Renin-Angiotensin-System (RAS)-Acting Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Renin-Angiotensin-System (RAS)-Acting Agent status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Renin-Angiotensin-System (RAS)-Acting Agent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Renin-Angiotensin-System (RAS)-Acting Agent significant trends, drivers, influence factors in global and regions.

6. To analyze Renin-Angiotensin-System (RAS)-Acting Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Renin-Angiotensin-System (RAS)-Acting Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Renin-Angiotensin-System (RAS)-Acting Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Renin-Angiotensin-System (RAS)-Acting Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Renin-Angiotensin-System (RAS)-Acting Agent market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Renin-Angiotensin-System (RAS)-Acting Agent industry.

Chapter 3: Detailed analysis of Renin-Angiotensin-System (RAS)-Acting Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Renin-Angiotensin-System (RAS)-Acting Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Renin-Angiotensin-System (RAS)-Acting Agent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Renin-Angiotensin-System (RAS)-Acting Agent Industry Trends Table 2. Renin-Angiotensin-System (RAS)-Acting Agent Industry Drivers Table 3. Renin-Angiotensin-System (RAS)-Acting Agent Industry Opportunities and Challenges Table 4. Renin-Angiotensin-System (RAS)-Acting Agent Industry Restraints Table 5. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Share by Company (2021-2026) Table 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Company (k units) & (2021-2026) Table 8. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Company (2021-2026) Table 9. Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price (US$/unit) of Company (2021-2026) Table 10. Global Renin-Angiotensin-System (RAS)-Acting Agent Company Ranking, (2024-2026) & (USD Million) Table 11. Global Renin-Angiotensin-System (RAS)-Acting Agent Key Company Manufacturing Base & Headquarters Table 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Company, Product Type & Application Table 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Renin-Angiotensin-System (RAS)-Acting Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Angiotensin Converting Enzyme Inhibitors (ACEi) Table 18. Significant Companies of Angiotensin Receptor Blockers (ARBs) Table 19. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Type (2021-2026) & (k units) Table 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Type (2027-2032) & (k units) Table 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Type (2021-2026) Table 23. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Type (2027-2032) Table 24. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type (2021-2026) Table 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Heart Failure Table 30. Significant Companies of Chronic Kidney Disease Table 31. Significant Companies of Hypertension Table 32. Significant Companies of Other Table 33. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Application (2021-2026) & (k units) Table 35. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Application (2027-2032) & (k units) Table 36. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Application (2021-2026) Table 37. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Application (2027-2032) Table 38. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application (2021-2026) Table 42. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application (2027-2032) Table 43. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2026) & (k units) Table 45. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2021-2026) Table 46. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2027-2032) & (k units) Table 47. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2027-2032) Table 48. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Region (2021-2026) Table 51. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Region (2027-2032) Table 53. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Renin-Angiotensin-System (RAS)-Acting Agent Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (k units) Table 58. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2021-2026) Table 59. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032) & (k units) Table 60. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2027-2032) Table 61. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Market Share by Country (2021-2026) Table 63. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Market Share by Country (2027-2032) Table 65. Takeda Pharmaceutical Company Limited Company Information Table 66. Takeda Pharmaceutical Company Limited Business Overview Table 67. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 69. Takeda Pharmaceutical Company Limited Recent Development Table 70. Sanofi S.A. Company Information Table 71. Sanofi S.A. Business Overview Table 72. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 74. Sanofi S.A. Recent Development Table 75. Johnson & Johnson Company Information Table 76. Johnson & Johnson Business Overview Table 77. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 79. Johnson & Johnson Recent Development Table 80. Novartis AG Company Information Table 81. Novartis AG Business Overview Table 82. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 84. Novartis AG Recent Development Table 85. Merck & Co., Inc. Company Information Table 86. Merck & Co., Inc. Business Overview Table 87. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 89. Merck & Co., Inc. Recent Development Table 90. Pfizer, Inc. Company Information Table 91. Pfizer, Inc. Business Overview Table 92. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 94. Pfizer, Inc. Recent Development Table 95. Daiichi Sankyo Company,Limited Company Information Table 96. Daiichi Sankyo Company,Limited Business Overview Table 97. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 99. Daiichi Sankyo Company,Limited Recent Development Table 100. AstraZeneca plc Company Information Table 101. AstraZeneca plc Business Overview Table 102. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 104. AstraZeneca plc Recent Development Table 105. Bristol-Myers Squibb Company Company Information Table 106. Bristol-Myers Squibb Company Business Overview Table 107. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 109. Bristol-Myers Squibb Company Recent Development Table 110. Boehringer lngelheim GmbH Company Information Table 111. Boehringer lngelheim GmbH Business Overview Table 112. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio Table 114. Boehringer lngelheim GmbH Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Renin-Angiotensin-System (RAS)-Acting Agent Distributors List Table 118. Renin-Angiotensin-System (RAS)-Acting Agent Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Renin-Angiotensin-System (RAS)-Acting Agent Product Image Figure 2. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032) & (US$ Million) Figure 4. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (2021-2032) & (k units) Figure 5. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Angiotensin Converting Enzyme Inhibitors (ACEi) Image Figure 10. Angiotensin Receptor Blockers (ARBs) Image Figure 11. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Type (2021-2032) Figure 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type (2021-2032) Figure 17. Heart Failure Image Figure 18. Chronic Kidney Disease Image Figure 19. Hypertension Image Figure 20. Other Image Figure 21. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Application (2021-2032) Figure 24. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application (2021-2032) Figure 27. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032) & (US$ Million) Figure 32. North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032) & (US$ Million) Figure 38. South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Renin-Angiotensin-System (RAS)-Acting Agent Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Renin-Angiotensin-System (RAS)-Acting Agent Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Angiotensin Converting Enzyme Inhibitors (ACEi)
  • Angiotensin Receptor Blockers (ARBs)
Applications
  • Heart Failure
  • Chronic Kidney Disease
  • Hypertension
  • Other
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Daiichi Sankyo Company,Limited
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Boehringer lngelheim GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032)
  4. 1.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume (2021-2032)
  5. 1.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Renin-Angiotensin-System (RAS)-Acting Agent Market Dynamics
  1. 2.1 Renin-Angiotensin-System (RAS)-Acting Agent Industry Trends
  2. 2.2 Renin-Angiotensin-System (RAS)-Acting Agent Industry Drivers
  3. 2.3 Renin-Angiotensin-System (RAS)-Acting Agent Industry Opportunities and Challenges
  4. 2.4 Renin-Angiotensin-System (RAS)-Acting Agent Industry Restraints
3 Renin-Angiotensin-System (RAS)-Acting Agent Market by Company
  1. 3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Company Revenue Ranking in 2025
  2. 3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Company (2021-2026)
  3. 3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Company (2021-2026)
  4. 3.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Company (2021-2026)
  5. 3.5 Global Renin-Angiotensin-System (RAS)-Acting Agent Company Ranking (2024-2026)
  6. 3.6 Global Renin-Angiotensin-System (RAS)-Acting Agent Company Manufacturing Base and Headquarters
  7. 3.7 Global Renin-Angiotensin-System (RAS)-Acting Agent Company Product Type and Application
  8. 3.8 Global Renin-Angiotensin-System (RAS)-Acting Agent Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Renin-Angiotensin-System (RAS)-Acting Agent Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Renin-Angiotensin-System (RAS)-Acting Agent Market by Type
  1. 4.1 Renin-Angiotensin-System (RAS)-Acting Agent Type Introduction
  2. 4.1.1 Angiotensin Converting Enzyme Inhibitors (ACEi)
  3. 4.1.2 Angiotensin Receptor Blockers (ARBs)
  4. 4.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Type
  5. 4.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Type
  9. 4.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Type (2021-2032)
  11. 4.3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type (2021-2032)
5 Renin-Angiotensin-System (RAS)-Acting Agent Market by Application
  1. 5.1 Renin-Angiotensin-System (RAS)-Acting Agent Application Introduction
  2. 5.1.1 Heart Failure
  3. 5.1.2 Chronic Kidney Disease
  4. 5.1.3 Hypertension
  5. 5.1.4 Other
  6. 5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Application
  7. 5.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Application
  11. 5.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Application (2021-2032)
  13. 5.3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application (2021-2032)
6 Renin-Angiotensin-System (RAS)-Acting Agent Regional Sales and Value Analysis
  1. 6.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region: 2021-2026
  4. 6.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2027-2032)
  5. 6.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Region (2021-2032)
  7. 6.4.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Region: 2021-2026
  8. 6.4.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Region (2027-2032)
  9. 6.5 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032)
  12. 6.6.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032)
  15. 6.7.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032)
  21. 6.9.2 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Country, 2025 VS 2032
7 Renin-Angiotensin-System (RAS)-Acting Agent Country-level Sales and Value Analysis
  1. 7.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2032)
  4. 7.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026)
  5. 7.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2027-2032)
  6. 7.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Country (2021-2032)
  7. 7.4.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Country (2021-2026)
  8. 7.4.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Renin-Angiotensin-System (RAS)-Acting Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company Limited
  2. 8.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 8.2 Sanofi S.A.
  8. 8.2.1 Sanofi S.A. Company Information
  9. 8.2.2 Sanofi S.A. Business Overview
  10. 8.2.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  12. 8.2.5 Sanofi S.A. Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Merck & Co., Inc.
  26. 8.5.1 Merck & Co., Inc. Company Information
  27. 8.5.2 Merck & Co., Inc. Business Overview
  28. 8.5.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  30. 8.5.5 Merck & Co., Inc. Recent Developments
  31. 8.6 Pfizer, Inc.
  32. 8.6.1 Pfizer, Inc. Company Information
  33. 8.6.2 Pfizer, Inc. Business Overview
  34. 8.6.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  36. 8.6.5 Pfizer, Inc. Recent Developments
  37. 8.7 Daiichi Sankyo Company,Limited
  38. 8.7.1 Daiichi Sankyo Company,Limited Company Information
  39. 8.7.2 Daiichi Sankyo Company,Limited Business Overview
  40. 8.7.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  42. 8.7.5 Daiichi Sankyo Company,Limited Recent Developments
  43. 8.8 AstraZeneca plc
  44. 8.8.1 AstraZeneca plc Company Information
  45. 8.8.2 AstraZeneca plc Business Overview
  46. 8.8.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  48. 8.8.5 AstraZeneca plc Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 8.10 Boehringer lngelheim GmbH
  56. 8.10.1 Boehringer lngelheim GmbH Company Information
  57. 8.10.2 Boehringer lngelheim GmbH Business Overview
  58. 8.10.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolio
  60. 8.10.5 Boehringer lngelheim GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Renin-Angiotensin-System (RAS)-Acting Agent Value Chain Analysis
  2. 9.1.1 Renin-Angiotensin-System (RAS)-Acting Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Renin-Angiotensin-System (RAS)-Acting Agent Sales Mode & Process
  6. 9.2 Renin-Angiotensin-System (RAS)-Acting Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Renin-Angiotensin-System (RAS)-Acting Agent Distributors
  9. 9.2.3 Renin-Angiotensin-System (RAS)-Acting Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst